2025
97. GLOBAL VARIATIONS IN ELECTROCONVULSIVE THERAPY USAGE: A COMPARATIVE CASE SERIES ON SCHIZOPHRENIA IN THE UNITED STATES
Park S, Kim J, Touponse S, Mandell A, Hong J, Crowell A, Hermida A, Kitay B, McDonald W, Posse P, Hershenberg R. 97. GLOBAL VARIATIONS IN ELECTROCONVULSIVE THERAPY USAGE: A COMPARATIVE CASE SERIES ON SCHIZOPHRENIA IN THE UNITED STATES. American Journal Of Geriatric Psychiatry 2025, 33: s71-s72. DOI: 10.1016/j.jagp.2025.04.099.Peer-Reviewed Original ResearchClinical Global Impression-SeverityClinical Global Impression-ImprovementBeck Depression InventoryElectroconvulsive therapy treatmentsTreatment-resistant depressionPatient Health Questionnaire-9Schizoaffective disorderElectroconvulsive therapyGAD-7Major depressionMood stabilizersECT treatmentDiagnosis of obsessive-compulsive disorderRemission of psychotic symptomsCGI-I scoreTreatment of schizophreniaECT initiationGeneralized Anxiety Disorder 7-itemObsessive-compulsive disorderSevere psychiatric conditionsStabilization of moodEffect of ECT treatmentECT literatureAutism spectrum disorderDegree of paranoiaGamified Attention Bias Modification Training to Augment Cognitive-Behavioral Therapy for Youth Anxiety Disorders: A Randomized Controlled Trial
Byrne M, Haller S, Linke J, Lewis K, Berman E, Henry L, Pagliaccio D, Quezada D, Meyer M, Abend R, Kircanski K, Silverman W, Lazarov A, Bar-Haim Y, Brotman M, Pine D. Gamified Attention Bias Modification Training to Augment Cognitive-Behavioral Therapy for Youth Anxiety Disorders: A Randomized Controlled Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2025 PMID: 40850530, PMCID: PMC12464829, DOI: 10.1016/j.jaac.2025.08.010.Peer-Reviewed Original ResearchAttention bias modification trainingPediatric Anxiety Rating ScaleCognitive-behavioral therapyFunctional magnetic resonance imagingBias modification trainingClinical Global Impression-ImprovementAmygdala connectivityAnxiety disordersModification trainingResponse to CBTYouth anxiety disordersAttentional bias taskAnxiety Rating ScaleSeed-based connectivityHealthy controlsTest-retest reliabilityAnxious youthBias taskPosttreatment anxietySymptom reductionNeural mechanismsTreatment respondersRandomized Controlled TrialsGroup differencesCortical regions
2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8
2017
Arbaclofen in fragile X syndrome: results of phase 3 trials
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann W, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear M, Carpenter R. Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal Of Neurodevelopmental Disorders 2017, 9: 3. PMID: 28616094, PMCID: PMC5467054, DOI: 10.1186/s11689-016-9181-6.Peer-Reviewed Original ResearchClinical Global Impression-ImprovementFragile X syndromeClinical Global Impression-SeveritySocial avoidanceABC-CFXAberrant Behavior Checklist-Community EditionHigh dose groupAnimal models of fragile X syndromeX syndromeModel of fragile X syndromeVineland Adaptive Behavior ScalesEffect sizeFlexible dose trialSerotonin reuptake inhibitorsSocial Avoidance subscaleChild studiesAdaptive Behavior ScalesAdolescent/adult studyFixed dose trialsDose groupParenting Stress IndexPhase 3 placebo-controlled trialsPreclinical models to clinical trialsResults of phase 3 trialsDose trial
2006
AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B. AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychopharmacology 2006, 16: 589-598. PMID: 17069547, DOI: 10.1089/cap.2006.16.589.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic alpha-AgonistsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildChild Development Disorders, PervasiveChild, PreschoolFemaleGuanfacineHumansMaleMethylphenidatePersonality AssessmentPilot ProjectsProspective StudiesTreatment FailureTreatment OutcomeConceptsOpen-label trialAberrant Behavior ChecklistPervasive developmental disorderClinical Global Impression-ImprovementHyperactivity subscaleEfficacy of guanfacinePlacebo-controlled trialCommon adverse effectsWeeks of treatmentTreatment of hyperactivityDevelopmental disordersBlood pressureOpen trialMean ageSleep disturbancesCommon complaintClinical practiceGuanfacineHyperactivityPilot studyAdverse effectsTrialsBehavior ChecklistChildrenMethylphenidate
2003
Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials
ARNOLD L, VITIELLO B, MCDOUGLE C, SCAHILL L, SHAH B, GONZALEZ N, CHUANG S, DAVIES M, HOLLWAY J, AMAN M, CRONIN P, KOENIG K, KOHN A, MCMAHON D, TIERNEY E. Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2003, 42: 1443-1450. PMID: 14627879, DOI: 10.1097/00004583-200312000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAggressionAutistic DisorderChildClinical Trials as TopicDopamine AntagonistsDouble-Blind MethodEndpoint DeterminationFemaleHumansMaleObserver VariationParent-Child RelationsPlacebosResearch DesignRisperidoneSeverity of Illness IndexStereotyped BehaviorTreatment OutcomeConceptsAberrant Behavior Checklist-Irritability subscaleClinical trialsIrritability subscaleClinical Global Impression-ImprovementDouble-blind trialPediatric Psychopharmacology Autism NetworkChief complaintCommon symptomsTarget symptomsEfficacy assessmentIrritable behaviorSymptom categoriesRisperidoneChange scoresSymptomsEffect size dInterrater reliabilityTrialsPlaceboTreatment effectsClinical applicationPrimary measureConsumer-friendly wayWeeksAutism Network
2002
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal Of Medicine 2002, 347: 314-321. PMID: 12151468, DOI: 10.1056/nejmoa013171.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementAtypical antipsychotic agentsPlacebo groupSelf-injurious behaviorRisperidone groupAntipsychotic agentsAutistic disorderIrritability scoresDouble-blind trialPrimary outcome measureTreatment of adultsTraditional antipsychotic medicationsPercent decreaseSerious behavioral disturbancesAberrant Behavior ChecklistRisperidone therapyTardive dyskinesiaAntipsychotic medicationAverage weight gainOutcome measuresPositive responsePostsynaptic dopamineSerotonin receptorsBehavioral disturbancesSevere tantrums
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply